This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Divieti, P. Articles by Bringhurst, F. R. Search for Related Content PubMed PubMed Citation Articles by Divieti, P. Articles by Bringhurst, F. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL PARATHYROID HORMONE

Human PTH-(7-84) Inhibits Bone Resorption in Vitro Via Actions Independent of the Type 1 PTH/PTHrP Receptor

Endocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Paola Divieti, M.D., Ph.D., Endocrine Unit, Wellman 5, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114. E-mail: divieti{at}helix.mgh.harvard.edu

The linear sequence of intact mammalian PTH consists of 84 amino acids, of which only the most amino(N)-terminal portion, i.e. PTH-(1-34), is required for the classical actions of the hormone on mineral ion homeostasis mediated by the type 1 PTH/PTHrP receptor (PTH1R). Like the N-terminus, the carboxyl (C)-terminal sequence of PTH is highly conserved among species, and various circulating PTH C-fragments are generated by peripheral metabolism of intact PTH or are directly secreted, in a calcium-dependent manner, by the parathyroid glands. Certain synthetic PTH C-fragments exert actions on bone and cartilage cells that are not shared by PTH-(1-34), and specific binding of PTH C-peptides has been demonstrated in bone cells in which PTH1R expression was eliminated by gene targeting. The peptide human (h) PTH-(7-84) recently was shown to inhibit the calcemic actions of hPTH-(1-34) or hPTH-(1-84) in parathyroidectomized animals. To determine whether this anticalcemic effect of hPTH-(7-84) in vivo might result from direct actions on bone, we studied its effects on both resorption of intact bone in vitro and formation of osteoclasts in primary cultures of murine bone marrow. Human (h) PTH-(7-84) (300 nM) reduced basal 72-h release of preincorporated ⁴⁵Ca from neonatal mouse calvariae by 50% (9.6 ± 1.9% vs. 17.8 ± 5.7%; P < 0.001) and similarly inhibited resorption induced by hPTH-(1-84), hPTH-(1-34), 1,25-dihydroxyvitamin D₃ (VitD), PGE₂, or IL-11. In 12-d murine marrow cultures, both hPTH-(7-84) (300 nM) and hPTH-(39-84) (3000 nM) lowered VitD-dependent formation of osteoclast-like cells by 70%. On the contrary, these actions of hPTH-(7-84) were not observed with the PTH1R antagonists hPTH-(3-34)NH₂ and [L¹¹,D-W¹²,W²³,Y³⁶]hPTHrP-(7-36)NH₂, which, unlike hPTH-(7-84), did inhibit PTH1R-dependent cAMP accumulation in ROS 17/2.8 cells. We conclude that hPTH-(7-84), acting via receptors distinct from the PTH1R and presumably specific for PTH C-fragments, exerts a direct antiresorptive effect on bone that may be partly due to impaired osteoclast differentiation.

This article has been cited by other articles:

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				J. Jolette, C. E. Wilker, S. Y. Smith, N. Doyle, J. F. Hardisty, A. J. Metcalfe, T. B. Marriott, J. Fox, and D. S. Wells Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats Toxicol Pathol, December 1, 2006; 34(7): 929 - 940. [Abstract] [Full Text] [PDF]

				G. S. Bounoutas, H. Tawfeek, L. F. Frohlich, U.-i. Chung, and A. B. Abou-Samra Impact of Impaired Receptor Internalization on Calcium Homeostasis in Knock-In Mice Expressing a Phosphorylation-Deficient Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor Endocrinology, October 1, 2006; 147(10): 4674 - 4679. [Abstract] [Full Text] [PDF]

				J. Huan, K. Olgaard, L. B. Nielsen, and E. Lewin Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1923 - 1930. [Abstract] [Full Text] [PDF]

				P. A. Friedman and W. G. Goodman PTH(1-84)/PTH(7-84): a balance of power Am J Physiol Renal Physiol, May 1, 2006; 290(5): F975 - F984. [Abstract] [Full Text] [PDF]

				T. Arakawa, P. D'Amour, L. Rousseau, J.-H. Brossard, M. Sakai, H. Kasumoto, N. Igaki, T. Goto, T. Cantor, and M. Fukagawa Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 525 - 531. [Abstract] [Full Text] [PDF]

				P. D'Amour, A. Rakel, J.-H. Brossard, L. Rousseau, C. Albert, and T. Cantor Acute Regulation of Circulating Parathyroid Hormone (PTH) Molecular Forms by Calcium: Utility of PTH Fragments/PTH(1-84) Ratios Derived from Three Generations of PTH Assays J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 283 - 289. [Abstract] [Full Text] [PDF]

				T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, A. Rakel, L. Rousseau, C. Albert, and T. Cantor Evidence That the Amino-Terminal Composition of Non-(1-84) Parathyroid Hormone Fragments Starts before Position 19 Clin. Chem., January 1, 2005; 51(1): 169 - 176. [Abstract] [Full Text] [PDF]

				J. J. Kazama, K. Omori, N. Higuchi, N. Takahashi, Y. Ito, H. Maruyama, I. Narita, T. L. Cantor, P. Gao, and F. Gejyo Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism Nephrol. Dial. Transplant., April 1, 2004; 19(4): 892 - 897. [Abstract] [Full Text] [PDF]

				R. C. Gensure, B. Ponugoti, Y. Gunes, M. R. Papasani, B. Lanske, M. Bastepe, D. A. Rubin, and H. Juppner Identification and Characterization of Two Parathyroid Hormone-Like Molecules in Zebrafish Endocrinology, April 1, 2004; 145(4): 1634 - 1639. [Abstract] [Full Text] [PDF]

				M. Inaba, K. Nakatsuka, Y. Imanishi, M. Watanabe, Y. Mamiya, E. Ishimura, and Y. Nishizawa Technical and Clinical Characterization of the Bio-PTH (1-84) Immunochemiluminometric Assay and Comparison with a Second-Generation Assay for Parathyroid Hormone Clin. Chem., February 1, 2004; 50(2): 385 - 390. [Abstract] [Full Text] [PDF]

				F. R. Bringhurst Circulating Forms of Parathyroid Hormone: Peeling Back the Onion Clin. Chem., December 1, 2003; 49(12): 1973 - 1975. [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, L. Rousseau, L. Roy, P. Gao, and T. Cantor Amino-Terminal Form of Parathyroid Hormone (PTH) with Immunologic Similarities to hPTH(1-84) Is Overproduced in Primary and Secondary Hyperparathyroidism Clin. Chem., December 1, 2003; 49(12): 2037 - 2044. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]

				S. J. Silverberg, P. Gao, I. Brown, P. LoGerfo, T. L. Cantor, and J. P. Bilezikian Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1-84) in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4725 - 4730. [Abstract] [Full Text] [PDF]

				J. C. Estepa, I. Lopez, A. J. Felsenfeld, P. Gao, T. Cantor, M. Rodriguez, and E. Aguilera-Tejero Dynamics of secretion and metabolism of PTH during hypo- and hypercalcaemia in the dog as determined by the 'intact' and 'whole' PTH assays Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1101 - 1107. [Abstract] [Full Text] [PDF]

				Y. Hatakeyama, K. Mizunashi, Y. Furukawa, S. Yabuki, Y. Sato, and T. Igarashi Plasma Levels of Parathyroid Hormone (1-84) Whole Molecule and Parathyroid Hormone (7-84)-Like Fragments in Pseudohypoparathyroidism Type I J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2250 - 2255. [Abstract] [Full Text] [PDF]

				A. H. Terry, J. Orrock, and A. W. Meikle Comparison of Two Third-Generation Parathyroid Hormone Assays Clin. Chem., February 1, 2003; 49(2): 336 - 337. [Full Text] [PDF]

				W. G. Goodman, I. B. Salusky, and H. Juppner New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1731 - 1736. [Full Text] [PDF]